MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ
1.420
-0.060
-4.05%
Opening 13:22 02/06 EST
OPEN
1.450
PREV CLOSE
1.480
HIGH
1.479
LOW
1.413
VOLUME
40.87K
TURNOVER
30.75K
52 WEEK HIGH
4.420
52 WEEK LOW
0.7600
MARKET CAP
27.48M
P/E (TTM)
-1.1827
1D
5D
1M
3M
1Y
5Y
Edesa gets Health Canada nod to start mid-stage study for vitiligo drug
Seeking Alpha · 5d ago
Edesa Biotech Receives Regulatory Approval For Phase 2 Vitiligo Study
Benzinga · 5d ago
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/18 12:50
Edesa Biotech Plunges on ACD Treatment News
TipRanks · 01/17 21:31
Nasdaq Edges Higher; Neovasc Shares Jump
Benzinga · 01/17 19:50
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/17 18:21
EH, APPH and ATXI among mid-day movers
Seeking Alpha · 01/17 17:56
Edesa Biotech's Dermatitis Study Data Fails To Cheer Investors
Benzinga · 01/17 17:30
More
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on inflammatory and immune-related diseases. The Company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, developing as a treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. ARDS can be caused by viral diseases, including Covid-19, bacterial pneumonia, sepsis, chest injury and other causes. Specifically, EB05 inhibits toll-like receptor 4 (TLR4), an immune signaling protein and an important mediator of inflammation that has been shown to be activated by SARS-COV2 as well as other respiratory infections, such as influenza. In addition to EB05, the Company is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness.

Webull offers kinds of Edesa Biotech Inc stock information, including NASDAQ:EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.